HOME >> MEDICINE >> NEWS
Novel antibiotic provides rapid relief from symptoms of tonsillitis/pharyngitis, study shows

Ketek (telithromycin), a novel compound from a new family of antibiotics, administered once daily for five days to patients suffering from tonsillitis/pharyngitis, provided equivalent clinical and bacteriological outcomes as those observed in patients receiving a 10-day course of treatment with penicillin V, a new study shows.

The more rapid symptom relief achieved with Ketek, the first antibiotic from the ketolide family to be developed for clinical use, may suggest a potential for a faster return to usual activities, and fewer days lost from work or school, for people with tonsillitis/pharyngitis resulting from group A b-haemoliytic streptococcus (GABHS) bacteria. GABHS is the most common bacterial cause of tonsillitis/pharyngitis.

The study results, reported today at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Istanbul, Turkey, were among several scientific presentations involving Ketek.

"This is an important study as it demonstrates the clinical and bacteriological effectiveness and symptom relief of Ketek in treating what is a very common upper respiratory tract infection," said Dr. Joanne Chang, Aventis Pharma.

The double-blinded study enrolled 396 patients between the ages of 15 and 65 with clinical signs and symptoms of acute tonsillopharyngitis, and who either had a positive streptococcal A antigen test or a positive throat culture for GABHS. These patients were randomized (198 patients to each group) to receive either 800 mg once daily Ketek followed by placebo for five days, or penicillin V 500 mg three-times daily for 10 days. Clinical and bacteriological outcomes were assessed at post-therapy (days 16-21) and late post-therapy (days 38-45).

At the post-therapy visit, bacteriological outcome was satisfactory in 79.7 percent and 79.3 percent of patients, and clinical cure was achieved in 85.9 percent and 85.8 percent of patients in the Ketek (198 patients) and penicillin V (197
'"/>

Contact: Liz Rickard
elizabeth.rickard@ketchum.com
44-0-20-7611-3633
Ketchum
4-Apr-2001


Page: 1 2

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel drugs help solve Gleevec resistance
5. Novel imaging technique shows abnormal brain anatomy in children with ADHD
6. Novel drug-antidote strategy provides greater control of drug action
7. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
8. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
9. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
10. Novel findings about neovessel formation
11. Novel MRI technique provides clear images of blood flow

Post Your Comments:
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... 17, 2014  UBM Medica US announces that ... and other clinicians who treat patients with type ... effective use of insulin .  Nearly ... replacement therapy – daily injections of one or ... in the function of pancreatic beta cells. Insulin is ...
(Date:10/17/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... biopharmaceutical company in China , ... from the China Food and Drug Administration (the ... concentrate ("PCC") at its Shandong Taibang facility. The ... facility for Good Manufacturing Practices ("GMP") compliance in ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
Cached News: